Cargando…
Evolution of (18)F-FDG PET/CT Findings in Patients After COVID-19: An Initial Investigation
The aim of this study was to assess the temporal evolution of pulmonary (18)F-FDG uptake in patients with coronavirus disease 2019 (COVID-19) and post–COVID-19 lung disease (PCLD). Methods: Using our hospital’s clinical electronic records, we retrospectively identified 23 acute COVID-19, 18 PCLD, an...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society of Nuclear Medicine
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805777/ https://www.ncbi.nlm.nih.gov/pubmed/34272318 http://dx.doi.org/10.2967/jnumed.121.262296 |
_version_ | 1784643293805543424 |
---|---|
author | Thornton, Andrew Fraioli, Francesco Wan, Simon Garthwaite, Helen S. Ganeshan, Balaji Shortman, Robert I. Endozo, Raymond Vöö, Stefan Kayani, Irfan Neriman, Deena Menezes, Leon Bomanji, Jamshed Hilllman, Toby Heightman, Melissa Porter, Joanna C. Groves, Ashley M. |
author_facet | Thornton, Andrew Fraioli, Francesco Wan, Simon Garthwaite, Helen S. Ganeshan, Balaji Shortman, Robert I. Endozo, Raymond Vöö, Stefan Kayani, Irfan Neriman, Deena Menezes, Leon Bomanji, Jamshed Hilllman, Toby Heightman, Melissa Porter, Joanna C. Groves, Ashley M. |
author_sort | Thornton, Andrew |
collection | PubMed |
description | The aim of this study was to assess the temporal evolution of pulmonary (18)F-FDG uptake in patients with coronavirus disease 2019 (COVID-19) and post–COVID-19 lung disease (PCLD). Methods: Using our hospital’s clinical electronic records, we retrospectively identified 23 acute COVID-19, 18 PCLD, and 9 completely recovered (18)F-FDG PET/CT patients during the 2 peaks of the U.K. pandemic. Pulmonary (18)F-FDG uptake was measured as a lung target-to-background ratio (TBR(lung) = SUV(max)/SUV(min)) and compared with temporal stage. Results: In acute COVID-19, less than 3 wk after infection, TBR(lung) was strongly correlated with time after infection (r(s) = 0.81, P < 0.001) and was significantly higher in the late stage than in the early stage (P = 0.001). In PCLD, TBR(lung) was lower in patients treated with high-dose steroids (P = 0.003) and in asymptomatic patients (P < 0.001). Conclusion: Pulmonary (18)F-FDG uptake in COVID-19 increases with time after infection. In PCLD, pulmonary (18)F-FDG uptake rises despite viral clearance, suggesting ongoing inflammation. There was lower pulmonary (18)F-FDG uptake in PCLD patients treated with steroids. |
format | Online Article Text |
id | pubmed-8805777 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Society of Nuclear Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-88057772022-02-15 Evolution of (18)F-FDG PET/CT Findings in Patients After COVID-19: An Initial Investigation Thornton, Andrew Fraioli, Francesco Wan, Simon Garthwaite, Helen S. Ganeshan, Balaji Shortman, Robert I. Endozo, Raymond Vöö, Stefan Kayani, Irfan Neriman, Deena Menezes, Leon Bomanji, Jamshed Hilllman, Toby Heightman, Melissa Porter, Joanna C. Groves, Ashley M. J Nucl Med Brief Communication The aim of this study was to assess the temporal evolution of pulmonary (18)F-FDG uptake in patients with coronavirus disease 2019 (COVID-19) and post–COVID-19 lung disease (PCLD). Methods: Using our hospital’s clinical electronic records, we retrospectively identified 23 acute COVID-19, 18 PCLD, and 9 completely recovered (18)F-FDG PET/CT patients during the 2 peaks of the U.K. pandemic. Pulmonary (18)F-FDG uptake was measured as a lung target-to-background ratio (TBR(lung) = SUV(max)/SUV(min)) and compared with temporal stage. Results: In acute COVID-19, less than 3 wk after infection, TBR(lung) was strongly correlated with time after infection (r(s) = 0.81, P < 0.001) and was significantly higher in the late stage than in the early stage (P = 0.001). In PCLD, TBR(lung) was lower in patients treated with high-dose steroids (P = 0.003) and in asymptomatic patients (P < 0.001). Conclusion: Pulmonary (18)F-FDG uptake in COVID-19 increases with time after infection. In PCLD, pulmonary (18)F-FDG uptake rises despite viral clearance, suggesting ongoing inflammation. There was lower pulmonary (18)F-FDG uptake in PCLD patients treated with steroids. Society of Nuclear Medicine 2022-02 /pmc/articles/PMC8805777/ /pubmed/34272318 http://dx.doi.org/10.2967/jnumed.121.262296 Text en © 2022 by the Society of Nuclear Medicine and Molecular Imaging. https://creativecommons.org/licenses/by/4.0/Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml. |
spellingShingle | Brief Communication Thornton, Andrew Fraioli, Francesco Wan, Simon Garthwaite, Helen S. Ganeshan, Balaji Shortman, Robert I. Endozo, Raymond Vöö, Stefan Kayani, Irfan Neriman, Deena Menezes, Leon Bomanji, Jamshed Hilllman, Toby Heightman, Melissa Porter, Joanna C. Groves, Ashley M. Evolution of (18)F-FDG PET/CT Findings in Patients After COVID-19: An Initial Investigation |
title | Evolution of (18)F-FDG PET/CT Findings in Patients After COVID-19: An Initial Investigation |
title_full | Evolution of (18)F-FDG PET/CT Findings in Patients After COVID-19: An Initial Investigation |
title_fullStr | Evolution of (18)F-FDG PET/CT Findings in Patients After COVID-19: An Initial Investigation |
title_full_unstemmed | Evolution of (18)F-FDG PET/CT Findings in Patients After COVID-19: An Initial Investigation |
title_short | Evolution of (18)F-FDG PET/CT Findings in Patients After COVID-19: An Initial Investigation |
title_sort | evolution of (18)f-fdg pet/ct findings in patients after covid-19: an initial investigation |
topic | Brief Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805777/ https://www.ncbi.nlm.nih.gov/pubmed/34272318 http://dx.doi.org/10.2967/jnumed.121.262296 |
work_keys_str_mv | AT thorntonandrew evolutionof18ffdgpetctfindingsinpatientsaftercovid19aninitialinvestigation AT fraiolifrancesco evolutionof18ffdgpetctfindingsinpatientsaftercovid19aninitialinvestigation AT wansimon evolutionof18ffdgpetctfindingsinpatientsaftercovid19aninitialinvestigation AT garthwaitehelens evolutionof18ffdgpetctfindingsinpatientsaftercovid19aninitialinvestigation AT ganeshanbalaji evolutionof18ffdgpetctfindingsinpatientsaftercovid19aninitialinvestigation AT shortmanroberti evolutionof18ffdgpetctfindingsinpatientsaftercovid19aninitialinvestigation AT endozoraymond evolutionof18ffdgpetctfindingsinpatientsaftercovid19aninitialinvestigation AT voostefan evolutionof18ffdgpetctfindingsinpatientsaftercovid19aninitialinvestigation AT kayaniirfan evolutionof18ffdgpetctfindingsinpatientsaftercovid19aninitialinvestigation AT nerimandeena evolutionof18ffdgpetctfindingsinpatientsaftercovid19aninitialinvestigation AT menezesleon evolutionof18ffdgpetctfindingsinpatientsaftercovid19aninitialinvestigation AT bomanjijamshed evolutionof18ffdgpetctfindingsinpatientsaftercovid19aninitialinvestigation AT hilllmantoby evolutionof18ffdgpetctfindingsinpatientsaftercovid19aninitialinvestigation AT heightmanmelissa evolutionof18ffdgpetctfindingsinpatientsaftercovid19aninitialinvestigation AT porterjoannac evolutionof18ffdgpetctfindingsinpatientsaftercovid19aninitialinvestigation AT grovesashleym evolutionof18ffdgpetctfindingsinpatientsaftercovid19aninitialinvestigation |